C-reactive protein levels in stable COPD patients: a case-control study

Denise Rossato Silva¹,²
Marcelo Basso Gazzana¹,²
Marli Maria Knorst¹,²

¹Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Department of Pulmonary Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil

Background: Previous studies have documented that C-reactive protein (CRP) levels are increased in stable COPD patients. However, most studies have also shown that higher CRP levels are observed in patients with comorbidities like diabetes mellitus and cardiovascular disease. We aimed to investigate if CRP levels are increased in stable COPD patients, and if there is an association between CRP levels and pulmonary function tests and clinical characteristics.

Methods: We conducted a case-control study in a tertiary care, university-affiliated hospital. COPD patients and controls were matched for sex and age in a 2:1 matching ratio. We included only those patients who had quit smoking. CRP levels were determined and pulmonary function tests were performed in both the groups.

Results: A total of 60 COPD patients and 30 controls were included in the analysis. The study subjects had a mean age of 64.8±8.5 years in COPD group and 64.3±9.2 years in control group (P=0.214). The median of CRP levels was 3.17 mg/L (interquartile range [IQR]: 1.73–5.99 mg/L) in COPD group and 2.13 mg/L (IQR: 1.18–7.69 mg/L) in control group (P=0.370). There were 34 (56.7%) patients in COPD group and 14 (46.7%) patients in control group with CRP levels greater than 3 mg/dL (P=0.382). Using bivariate correlations, we found significant positive correlations in COPD patients between body mass index (BMI) and CRP (r=0.3, P=0.045), and between CRP and forced vital capacity (FVC, % of predicted) (r=0.3; P=0.023). In a multivariate model, female sex and FVC (% of predicted) were associated with a CRP value greater than 3 mg/dL in the COPD group.

Conclusion: The levels of CRP in the stable COPD patients were not significantly different when compared to those in the control subjects. Female sex and FVC (% predicted) were associated with CRP levels greater than 3 mg/dL in the COPD group.

Keywords: case-control study, chronic obstructive pulmonary disease, C-reactive protein, comorbidity

Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world, accounting for more than 3 million deaths annually.¹ Systemic inflammation and oxidative stress are the most important features of COPD. There is an increasing interest in determining the role of biomarkers of systemic inflammation in COPD patients, as these may have possible uses in evaluating exacerbations, monitoring disease progression, and measuring the effects of treatments.²⁻⁴ C-reactive protein (CRP) is a potential biomarker of systemic inflammation that is synthesized predominantly by the hepatocytes in response to tissue damage or inflammation.⁵ Several previous studies have documented that CRP levels are increased in stable COPD patients.⁶⁻¹² However, in most studies, patients with comorbidities like diabetes mellitus and cardiovascular disease, known to be associated with higher CRP levels, were not excluded.⁵,⁹,¹⁰ In addition, in stable COPD patients, CRP was
shown to be negatively correlated with forced expiratory volume in 1 second (FEV$_1$) and grade of dyspnea, but was not correlated with age. On the other hand, another study demonstrated that CRP had a weak correlation with COPD severity in elderly stable patients.

Given the conflicting results of prior studies, we aimed to investigate if CRP levels are increased in stable COPD patients, and if there is an association between CRP levels and pulmonary function tests and clinical characteristics.

**Methods**

We conducted a prospective case-control study in a general, tertiary care, university-affiliated hospital. COPD patients and controls were matched for sex and age in a 2:1 matching ratio. COPD was confirmed in patients with a FEV$_1$/FVC ratio of less than 0.7, measured 20 minutes after the administration of salbutamol. COPD severity was classified according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria. Patients were classified into low-risk groups (A and B) and high-risk groups (C and D) according to the GOLD 2011 classification. The body mass index, measure of airflow obstruction, dyspnea score and exercise capacity (BODE) index was calculated as described. Outpatients with COPD were sequentially enrolled. Patients with COPD, referred from primary care, had regular consultations in an outpatient clinic specific for COPD patients, localized inside the hospital. The control group consisted of volunteers recruited from the same hospital, who visited other outpatients’ clinics and had normal spirometry. Most of these volunteers had regular appointments for checkup and did not have any comorbidity.

We only included never or former smokers with an abstinence time of more than 6 months. COPD patients with an episode of exacerbation in the last 4 weeks were excluded. We also excluded patients and controls diagnosed with asthma or cancer in the last 5 years; current or former smokers with an abstinence time of less than 6 months; suspected diagnosis of acute inflammatory or infectious disease, surgery, or trauma in the last 30 days; diabetes; heart failure; chronic renal failure; pregnancy; stroke; and ischemic heart disease. The Ethics Committee from Hospital de Clínicas de Porto Alegre approved the study, and all subjects gave written informed consent to participate in the study.

The participants were interviewed and the following data were collected through a standardized questionnaire: demographic data, smoking habits, presence of comorbidities, and inhaled corticosteroid (ICS) and oral corticosteroid use. Pulmonary function tests, including spirometry, lung volumes, and diffusing capacity of the lung for carbon monoxide (DLCO), were performed using a computerized spirometer and a plethysmograph (Jäger, Würzburg, Germany) according to the American Thoracic Society/European Respiratory Society guidelines and previously published reference values. A spirometry with bronchodilator was performed in the control subjects. We described only post-bronchodilator values.

Blood sample was collected from all the participants and CRP levels were measured using a high sensitivity assay (Beckman Coulter, Inc., Miami, FL, USA), with a lower detection limit of 0.15 mg/L. For some statistical analysis, levels of CRP were categorized using the cut-point 3 mg/L, a cut-point previously used by others. Pulmonary function tests were performed in the same week that the blood measurements were taken.

Data analysis was performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). Data were presented as number of cases, mean ± standard deviation (SD), or median with interquartile range. Categorical comparisons were carried out by chi-square test using Yates’s correction if indicated or by Fisher’s exact test. Continuous variables were compared using the student’s t-test or Wilcoxon signed-rank test. Pearson’s (or Spearman’s when indicated) correlations were performed to evaluate for potential relationships between CRP levels and age, BMI, pulmonary function tests, and BODE index. Multivariate logistic regression analysis was performed using factors associated with CRP levels greater than 3 mg/dL in univariate analysis (P<0.20), controlled by sex and age. Hierarchical logistic regression models with predictors added one at a time were also examined to evaluate the possible collinearity among the predictors. The goodness-of-fit of the multiple logistic regression models was assessed using the Hosmer–Lemeshow test. Odds ratios (ORs) and nominal 95% confidence intervals (CIs) were presented. A two-sided P-value <0.05 was considered significant for all the analyses.

On the basis of data presented by de Torres et al, we estimated a sample size of 27 patients, under the assumptions of a type I error (two-sided) of 5% and a power of 80%, on comparison of CRP values between two groups (COPD vs control). In addition, to find a correlation (at least r=0.60) between CRP and other variables, with a power of 80% and significance at 5%, 19 patients would be required. Once these are small sample sizes, we decided to increase the number of cases and use a 1:2 control-to-case ratio. Wacholder et al suggested that the best way to increase precision in a case-control study is to increase the number of cases by widening the base geographically or temporally rather than by increasing the number of controls, because the marginal increase in precision resulting from an additional case is greater than that from an additional control.
Results
A total of 60 COPD patients and 30 controls met the inclusion criteria and were included in the analysis, after having given signed, informed consent. The characteristics of the study population are shown in Table 1.

The study subjects had a mean age of 64.8±8.5 years in the COPD group and 64.3±9.2 years in the control group (P=0.214). Patients with COPD had a lower body mass index (BMI) compared with control subjects (25.3±4.5 kg/m² vs 28.1±4.3 kg/m², P=0.006). There were 58 (96.7%) former smokers and two (3.3%) never smokers in the COPD group. In the control group, there were nine (30.0%) former smokers and 21 (70.0%) never smokers. The number of cigarettes smoked was higher in the COPD group (median =46.5 pack-years) than in the control group (median =30.0 pack-years), but this difference was not statistically significant (P=0.193). There were 20 (33.3%) patients with comorbidities in the COPD group: 17 (28.3%) with systemic arterial hypertension, nine (15.0%) with dyslipidemia, and six (10.0%) with osteoporosis. In control group, there were 28 (46.7%) patients with comorbidities: two had dyslipidemia, one had systemic arterial hypertension, and one had restless legs syndrome. All the subjects (both cases and controls) with dyslipidemia were using synvastatin.

As expected, patients diagnosed with COPD had FEV₁ (% of predicted) and FVC (% of predicted) values lower than the subjects in control group (P<0.0001). According to the GOLD criteria, there were two (3.3%), 20 (33.3%), 21 (35.0%), and 17 (28.3%) patients with stages I, II, III, and IV disease, respectively. According to the GOLD 2011 classification, there were ten (16.7%), six (10.0%), 16 (26.7%), and 28 (46.7%) patients in groups A, B, C, and D, respectively. The median BODE index was 3.0 (1.5–5.0).

The median of CRP values was 3.2 mg/L (IQR: 1.7–5.9 mg/L) in COPD group and 2.13 mg/L (IQR: 1.18–7.69 mg/L) in control group. This difference was not statistically significant (P=0.370). There were 34 (56.7%) patients in COPD group and 14 (46.7%) patients in control group with CRP levels greater than 3 mg/dL (P=0.382). Table 2 shows the characteristics of patients and controls with normal and abnormal CRP levels. Normal CRP levels were less frequent in females than in males (five [19.2%] vs 21 [80.8%], P=0.014). In the control group, the number of cigarettes smoked was higher in participants with abnormal

Table 1 Characteristics of patients with COPD and control subjects

<table>
<thead>
<tr>
<th>Parameters</th>
<th>COPD group (n=60)</th>
<th>Control group (n=30)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years)</td>
<td>64.8±8.5</td>
<td>64.3±9.2</td>
<td>0.214</td>
</tr>
<tr>
<td>Male (%)</td>
<td>38 (63.3)</td>
<td>20 (66.7)</td>
<td>0.755</td>
</tr>
<tr>
<td>Smoking pack-years</td>
<td>46.5 (20.6–65.5)</td>
<td>30.0 (7.5–45.5)</td>
<td>0.193</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>25.3±4.5</td>
<td>28.1±4.3</td>
<td>0.006</td>
</tr>
<tr>
<td>Inhaled corticosteroid users</td>
<td>40 (66.7)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Oral corticosteroid users</td>
<td>1 (1.7)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>C-reactive protein (mg/L)</td>
<td>3.2 (1.7–5.9)</td>
<td>2.1 (1.2–7.7)</td>
<td>0.620</td>
</tr>
<tr>
<td>Pulmonary function tests</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FVC (% of predicted)</td>
<td>70.1±22.8</td>
<td>99.7±13.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FEV₁ (% of predicted)</td>
<td>43.5±19.2</td>
<td>102.4±18.3</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>FEV₁/FVC</td>
<td>45.1±11.7</td>
<td>80.9±7.9</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>TLC (% of predicted)</td>
<td>122.1±23.3</td>
<td>NA</td>
<td>–</td>
</tr>
<tr>
<td>Dlco (% of predicted)</td>
<td>46.4±16.7</td>
<td>NA</td>
<td>–</td>
</tr>
<tr>
<td>Severity of COPD (GOLD criteria)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stage I</td>
<td>2 (3.3)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Stage II</td>
<td>20 (33.3)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Stage III</td>
<td>21 (35.0)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Stage IV</td>
<td>17 (28.3)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>BODE index</td>
<td>3.0 (1.5–5.0)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Exacerbations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>O or 1 in the last year</td>
<td>42 (70.0)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>≥2 in the last year</td>
<td>18 (30.0)</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Note: Data are presented as mean ± SD, n (%), or median (interquartile range).

Abbreviations: NA, not available; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; TLC, total lung capacity; Dlco, carbon monoxide diffusing capacity of the lung; GOLD, Global Initiative for Chronic Obstructive Lung Disease (stage I: FEV₁ ≥80% of predicted; II: 50% ≤ FEV₁ < 80% of predicted; III: 30% ≤ FEV₁ < 50% of predicted; IV: FEV₁ < 30% of predicted); BODE, body mass index, measure of airflow obstruction, dyspnea score and exercise capacity; SD, standard deviation.
Table 2 Characteristics of patients and controls with normal and abnormal C-reactive protein levels

<table>
<thead>
<tr>
<th>Parameters</th>
<th>COPD group (n=60)</th>
<th>Control group (n=30)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Abnormal CRP (n=34)</td>
<td>Normal CRP (n=26)</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>64.7±9.0</td>
<td>64.8±7.9</td>
</tr>
<tr>
<td>Female (%)</td>
<td>17 (50.0)</td>
<td>5 (19.2)</td>
</tr>
<tr>
<td>Smoking pack-years</td>
<td>41 (19.0–62.5)</td>
<td>51 (32.1–72.0)</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>25.7±5.1</td>
<td>24.7±3.5</td>
</tr>
<tr>
<td>Inhaled corticosteroid users</td>
<td>25 (73.5)</td>
<td>15 (57.7)</td>
</tr>
<tr>
<td>Two or more exacerbations in the past year</td>
<td>10 (29.4)</td>
<td>8 (30.8)</td>
</tr>
<tr>
<td>FVC (% of predicted)</td>
<td>60.7±16.4</td>
<td>70.2±20.9</td>
</tr>
<tr>
<td>FEV₁ (% of predicted)</td>
<td>36.3±14.3</td>
<td>40.1±16.9</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>44.8±12.1</td>
<td>46.2±11.1</td>
</tr>
<tr>
<td>BODE index</td>
<td>3.0 (1.0–5.3)</td>
<td>3.0 (2.0–5.0)</td>
</tr>
</tbody>
</table>

Severity of COPD (GOLD criteria)

- Stage I: 6 (17.6) vs 4 (15.4), P=0.66
- Stage II: 2 (5.9) vs 4 (15.4), P=–
- Stage III: 9 (26.5) vs 7 (26.9), P=–
- Stage IV: 17 (50.0) vs 11 (42.3), P=–

Notes: There was only one smoker in this subgroup. Data are presented as mean ± SD, n (%), or median (interquartile range).

Abbreviations: NA, not available; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; CRP, C-reactive protein; GOLD, Global Initiative for Chronic Obstructive Lung Disease (stage I: FEV₁ ≥80% of predicted; II: 50% ≤ FEV₁ < 80% of predicted; III: 30% ≤ FEV₁ < 50% of predicted; IV: FEV₁ < 30% of predicted); BODE, body mass index, measure of airflow obstruction, dyspnea score and exercise capacity; SD, standard deviation.

CRP (40 [35.0–79.5] pack-years) levels than in those with normal CRP (7.5 [3.0–24.4] pack-years) levels. There were no differences in CRP levels in COPD patients according to GOLD criteria, number of exacerbations in the last year, and ICS use. Only one patient was using oral corticosteroid and he had a normal CRP value (0.42).

Logistic regression analysis, estimating the odds ratios (ORs) of risk of having a CRP value greater than 3 mg/dL (abnormal CRP), was conducted for patients and controls separately. The variables such as age, sex, smoking pack-years, FVC (% of predicted), and FEV₁ (% of predicted) were included in the model. Only female sex (OR: 6.85, 95% CI: 1.7–27.5; P=0.054) was found to be associated with abnormal CRP levels in the multivariate model.

Using bivariate correlations, we found significant positive correlations between BMI and CRP in COPD patients (r=0.30, P=0.045) (Table 3). There was no correlation between CRP and BMI in control group (P=0.097). In COPD patients, correlation was found between CRP and FVC (% of predicted) (r=–0.3; P=0.023). In both COPD and control groups, no correlation was observed between FEV₁ (% of predicted) and CRP (r=–0.094 and P=0.473 for COPD group; r=–0.20 and P=0.323 for control group).

Table 3 Bivariate correlations with C-reactive protein in COPD patients and controls

<table>
<thead>
<tr>
<th>Parameters</th>
<th>COPD group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r</td>
<td>P-value</td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>–0.008</td>
<td>0.952</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>0.3</td>
<td>0.045*</td>
</tr>
<tr>
<td>Pulmonary function tests</td>
<td>–0.3</td>
<td>0.023*</td>
</tr>
<tr>
<td>FVC (% of predicted)</td>
<td>–0.094</td>
<td>0.473</td>
</tr>
<tr>
<td>FEV₁ (% of predicted)</td>
<td>0.2</td>
<td>0.153</td>
</tr>
<tr>
<td>FEV₁/FVC (%)</td>
<td>0.003</td>
<td>0.984</td>
</tr>
<tr>
<td>DlCo (% of predicted)</td>
<td>0.043</td>
<td>0.764</td>
</tr>
<tr>
<td>BODE index</td>
<td>0.050</td>
<td>0.713</td>
</tr>
</tbody>
</table>

Notes: *P<0.05.

Abbreviations: NA, not available; COPD, chronic obstructive pulmonary disease; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; TLC, total lung capacity; DlCo, carbon monoxide diffusing capacity of the lung; BODE, body mass index, measure of airflow obstruction, dyspnea score and exercise capacity.
Discussion

In this case-control study, we aimed to evaluate if CRP levels were different in clinically stable COPD and control subjects, and whether there was an association between pulmonary function tests and CRP. We demonstrated that CRP levels were not statistically different between COPD patients and controls. In a multivariate model, female sex and FVC (% predicted) were associated with a CRP value greater than 3 mg/dL in COPD group. Also, using bivariate correlations, we found significant positive correlations between BMI and CRP, and between FVC (% of predicted) and CRP in the COPD patients.

Several studies have demonstrated that concentration of CRP is increased in clinically stable COPD patients as compared to healthy controls. However, CRP is an acute phase protein and is elevated during many conditions. It is well known that patients with COPD have a higher risk of developing cardiovascular diseases and cardiovascular-related death. Systemic inflammation has a role in endothelial dysfunction and is associated with the risk of cardiovascular diseases and mortality. In addition, higher CRP levels were found in patients with diabetes mellitus and cardiovascular disease. Data on these comorbidities were not collected in some studies that showed increased levels of CRP in COPD patients. Therefore, the possibility of residual confounding cannot be completely excluded. We did not find difference in CRP levels between cases and controls, but we excluded patients with the most common comorbidities related to chronic inflammation, such as cardiovascular disease, diabetes mellitus, cancer, and current smoking.

In the present study, there was no difference in CRP concentrations between groups of COPD patients when subdivided according to the severity of the disease. It has been previously described that patients with COPD had serum CRP levels higher than those in healthy controls, and that patients with severe COPD had serum CRP levels higher than those with moderate COPD. Serum CRP concentrations were significantly higher in COPD patients (stages III and IV) compared to patients in stage I or II. The small sample size in each subgroup of severity precludes a definitive conclusion in our study.

CRP and FVC (% of predicted) values were weekly correlated in our study, and FVC (% of predicted) was associated with abnormal CRP levels in a multivariate analysis. The negative associations between CRP and FVC have been previously demonstrated in several studies. It was found that as lung function improved, systemic inflammation declined, and as the inflammation increased, the lung function deteriorated. The possible mechanism involved in this association is that chronic inflammation enhances telomere shortening, which in turn leads to senescence of lung alveolar and endothelial cells. In addition, systemic inflammation induces endothelial dysfunction, resulting in pulmonary vascular infiltration and lung tissue damage.

We found a positive, although weak, correlation between BMI and CRP levels in COPD patients. Elevated levels of CRP have been reported in overweight adults. Several studies have demonstrated a positive relationship between CRP levels and BMI in COPD patients. Obese COPD patients (BMI ≥ 30 kg/m²) were 3.3 times more likely to have highly elevated CRP levels compared to those of normal weight (BMI 21–24.9 kg/m²). However, according to the logistic regression analysis conducted in this study, BMI was not associated with abnormal CRP levels. Maybe in another study it will be more accurate to match the groups also on BMI.

In our study, normal CRP levels were less frequent in woman than in men in the COPD group. One study showed that female sex was associated with increased CRP levels. A sex-related effect on CRP levels was also found in the analysis of NHANES data, with higher levels in females. A heightened inflammatory response due to cigarette smoking in woman may explain this finding. We excluded current smokers, but the inflammatory response in the airways in COPD patients may persist even after smoking cessation. This could explain the effect of lifetime smoking (pack-years) on CRP levels in our control group. Smoking pack-years were significant predictors of CRP levels in a previous investigation. Several studies have shown that current smokers have higher CRP levels than nonsmokers, and that there is a positive association with the number of pack-years smoked.

We could not find an association between ICS use and CRP levels, although a previous study showed that CRP levels were lower in COPD patients treated with ICS than in those who were not treated. The number of exacerbations was also not associated with CRP levels in our study, which could be related to the small number of patients with two or more exacerbations in the past year. Nevertheless, no difference was shown in CRP levels between frequent and infrequent exacerbators in another report.

Our study includes some limitations. First, the investigation was done in a single center, and was conducted with a small sample size. In addition, we excluded active smokers from cases and from controls, because it was previously demonstrated that CRP levels were significantly higher for current smokers compared with former smokers and never smokers. However, exclusion of active smokers...
affects the generalization of our results, because in clinical practice, there are many patients with COPD who still smoke. Furthermore, we did not measure other systemic biomarkers that may be of interest in COPD and more sensitive than CRP. Finally, there were only two patients with COPD stage I in our study, so that our results might not be valid to this subgroup of patients. On the other hand, the strength of the present study is that we excluded patients with the most common comorbidities related to chronic inflammation, which can influence CRP levels.

Conclusion
In conclusion, we found that levels of CRP in stable COPD were not different as compared to control subjects. In addition, in a multivariate model, female sex and FVC (% predicted) were associated with a CRP level greater than 3 mg/dL in the COPD group. These results if confirmed in a larger study, which also excludes patients with comorbidities related to chronic inflammation, could contribute to a better understanding of CRP concentrations in COPD patients.

Acknowledgment
Funding for this study was provided by FIPE-HCPA (Fundo de Incentivo à Pesquisa – Hospital de Clínicas de Porto Alegre). The FIPE-HCPA had no further role in study design; in the writing of the report; or in the decision to submit the paper for publication.

Author contributions
DRS carried out literature search, data collection, study design, analysis of data, and manuscript preparation. MBG contributed to literature search, study design, and review of the paper. MMK contributed to literature search, study design, analysis of data, and review of the paper. All authors contributed toward data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest in this work.

References


---

**International Journal of COPD**

**Publish your work in this journal**

The International Journal of COPD is an international, peer-reviewed journal of therapeutics and pharmacology focusing on concise rapid reporting of clinical studies and reviews in COPD. Special focus is given to the pathophysiological processes underlying the disease, intervention programs, patient focused education, and self management protocols.

**Submit your manuscript here:** [http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal](http://www.dovepress.com/international-journal-of-chronic-obstructive-pulmonary-disease-journal)